Adding an AI Device to Your Catalog? What a 510(k) Clearance Does — and Doesn't — Guarantee

For a category buyer, an "FDA cleared" AI device looks like a de-risked SKU: the regulator said yes, the vendor has a certificate, the margin looks good. The clearance is genuinely necessary — but it guarantees less than most catalog decisions assume, and the gap is where returns, warranty exposure, and brand damage hide.

Quick answer

A 510(k) clearance guarantees one thing: the FDA found the device substantially equivalent to a legally marketed predicate for a specific intended use. It does not guarantee clinical superiority, commercial demand, manufacturing quality at scale, or that the vendor's marketing matches what was cleared. Those four gaps are the buyer's diligence, not the FDA's.

What the clearance actually covers

The 510(k) record — public, and quick to pull at accessdata.fda.gov — establishes that the device may be legally marketed in the US, bounded by the intended use the FDA cleared.

But the record page itself is an index card: applicant, device name, product code, decision date, decision. The substance sits in the document it links. Open the 510(k) summary — that is where the cleared intended-use statement appears, and where the predicate the equivalence argument rests on is named. For an AI product, read that intended-use statement twice: most cleared AI software is assistance, triage, or workflow prioritization with a clinician in the loop, not autonomous diagnosis. (Sponsors may file a statement rather than a summary, in which case the detail is not posted and must be requested from the sponsor.)

The four gaps a clearance leaves open

1. Claims drift. A sales deck can promise more than the clearance covers. Anything beyond the cleared intended use is a claim the FDA never reviewed — and one your reps would be repeating downstream. Compare the deck to the summary line by line before the SKU goes live; under FDA's rules, how a device is promoted is itself evidence of its intended use.
2. No superiority finding. "Substantially equivalent" is a comparison to a predicate, not a performance ranking. A cleared device can be legally sold and still underdeliver clinically. Ask for real-world performance evidence separately.
3. Regulatory posture is not product maturity. A first-time sponsor with one clearance may have no field history, no quality track record at volume, and no practice at handling complaints, corrections, or software updates under FDA rules. Ask how each of those is staffed and documented.
4. A cleared category is not a demanded category. Authorization volume in AI software has grown steeply — we counted it — which proves regulatory feasibility, not that your customers are asking for the SKU. Separate the regulatory signal from the demand signal before committing shelf and rep time.

Questions that separate strong suppliers from risky ones

• What is the submission number, and does the cleared intended use in the summary match every claim in your sales material?
• Which predicate did you clear against, and why is it the right comparison?
• How do you evaluate software updates — what magnitude of change triggers a new submission?
• How do you handle complaints and adverse-event reporting, and what does your correction-and-removal process look like?
• What real-world performance data exists beyond the submission?

A supplier who answers these fluently is telling you they understand the regulated market they are asking you to carry them into. A supplier who leads with "we're FDA registered" is telling you something too — registration is an establishment formality that involves no product review at all. (The distinctions between cleared, approved, granted, and registered are worth keeping straight.)

None of this is legal advice; it is the diligence a category team can run from public records before the lawyers get involved.

We read the FDA's AI-in-medicine record weekly and publish what moves, free. If there's a category question you'd want taken to the record, send it over.

Common questions